Searched for: in-biosketch:true
person:hochmj03
Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in Patients With Advanced Chronic Kidney Disease: ISCHEMIA-CKD EXTEND
Bangalore, Sripal; Maron, David J; Anthopolos, Rebecca; Reynolds, Harmony R; Xu, Yifan; Chang, Michelle; Boumakis, Stephanie; Lopez-Sendon, Jose; Senior, Roxy; Goodman, Shaun G; O'Brien, Sean M; Fleg, Jerome L; Hochman, Judith S; ,
BACKGROUND/UNASSIGNED:In the ISCHEMIA-CKD trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease), at a median follow-up of 2.2 years, the primary composite outcome of death or nonfatal myocardial infarction was similar between an initial invasive strategy (INV) compared with an initial conservative strategy (CON) in patients with moderate or severe myocardial ischemia and advanced chronic kidney disease. However, the long-term outcomes comparing the 2 strategies are unknown. METHODS/UNASSIGNED:Participants in the ISCHEMIA-CKD trial were randomly assigned to either INV, involving coronary angiography and revascularization when feasible, added to guideline-directed medical therapy or to CON with guideline-directed medical therapy alone and invasive procedures reserved for failure of guideline-directed medical therapy. After the active intervention trial phase, long-term vital status follow-up was conducted through participant contact by participating sites and by health record and centralized death database searches. The primary outcome for the extended follow-up phase was all-cause mortality. Secondary outcomes were cause-specific mortality, including cardiovascular and noncardiovascular mortality. RESULTS/UNASSIGNED:Among the 777 participants randomized (388 to INV and 389 to CON), over a median of 8 years of follow-up, vital status retention among survivors was 95%. There was a total of 429 deaths (55%). Cumulative all-cause mortality (57.4% versus 56.8%; adjusted hazard ratio, 1.05 [95% CI, 0.87-1.28]) or cardiovascular mortality (40.3% versus 38.4%; adjusted hazard ratio, 1.06 [95% CI, 0.84-1.34]) at 8 years did not differ between INV and CON. The restricted mean survival time was 1941 days (1834-2047 days) for INV versus 1990 days (1885-2094 days) for CON, with an adjusted estimated difference of -99 days (-245 to 46). The posterior probability of at least a 1 percentage point lower or higher death with INV at the 8-year median follow-up was 28% and 52%, respectively. Similarly, the posterior probability of at least a 1 percentage point lower or higher cardiovascular mortality with INV was 23% and 56%, respectively. CONCLUSIONS/UNASSIGNED:In patients with at least moderate ischemia and advanced chronic kidney disease, there was no significant long-term benefit of an initial INV at reducing the risk of all-cause or cardiovascular mortality compared with an initial conservative strategy. REGISTRATION/UNASSIGNED:URL: https://www.clinicaltrials.gov; Unique identifier: NCT01985360.
PMID: 42998238
ISSN: 1524-4539
CID: 6075521
Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in ISCHEMIA-EXTEND
Hochman, Judith S; Anthopolos, Rebecca; Reynolds, Harmony R; Bangalore, Sripal; Xu, Yifan; O'Brien, Sean M; Boumakis, Stephanie; Chang, Michelle; Rosenberg, Yves; Senior, Roxy; Banfield, Ann; Goodman, Shaun G; Lopes, Renato D; Pracon, Radoslaw; Lopez-Sendon, Jose; Steg, P Gabriel; Maggioni, Aldo Pietro; Newman, Jonathan D; Berger, Jeffrey S; Sidhu, Mandeep S; White, Harvey D; Troxel, Andrea B; Harrington, Robert A; Boden, William E; Stone, Gregg W; Mark, Daniel B; Spertus, John A; Maron, David J; ,
IMPORTANCE/UNASSIGNED:It is unknown whether routine invasive management of chronic coronary disease improves long-term survival when added to guideline-directed medical therapy. OBJECTIVE/UNASSIGNED:To compare the effects of initial invasive and conservative strategies on long-term mortality in patients with chronic coronary disease. DESIGN, SETTING, AND PARTICIPANTS/UNASSIGNED:In this long-term follow-up study of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA), an international trial of patients with chronic coronary disease, moderate or severe ischemia, left ventricular ejection fraction of 35% or more, and no left main coronary artery disease, unacceptable angina, or recent acute coronary syndrome, participants were randomized at 320 sites in 37 countries beginning August 2012 and followed up through December 2025. Data were analyzed using the intention-to-treat principle. INTERVENTION/UNASSIGNED:ISCHEMIA randomized patients to an initial invasive strategy of guideline-directed medical therapy plus coronary angiography and revascularization (when feasible) or an initial conservative strategy with guideline-directed medical therapy alone, with invasive management for failure of medical therapy. MAIN OUTCOMES AND MEASURES/UNASSIGNED:All-cause, cardiovascular, and noncardiovascular mortality were analyzed using cumulative incidence estimates, Cox and Fine-Gray models, bayesian analysis, and restricted mean survival time. RESULTS/UNASSIGNED:Among 5179 participants, median age was 64 (IQR, 58-70) years; 23% were female, 42% had diabetes, and median ejection fraction was 60% (IQR, 55%-65%). During 9-year median follow-up (range, 1 day to 13.4 years), 1071 deaths occurred (782 during extended follow-up): 672 cardiovascular, 359 noncardiovascular, and 40 unclassified. All-cause 11-year mortality was not significantly different between groups (25.8% invasive vs 26.9% conservative; estimated difference, -1.0 percentage point [95% CI, -4.2 to 2.1 percentage points]; adjusted hazard ratio [AHR], 0.97 [95% CI, 0.86-1.09]). By bayesian analysis, the posterior probability of more than 1 percentage-point survival benefit to invasive vs conservative was low (18%). Cardiovascular mortality at 11 years was 15.8% in the invasive group vs 17.1% in the conservative group (estimated difference, -1.4 percentage points [95% CI, -4.0 to 1.3 percentage points]; AHR, 0.88 [95% CI, 0.75-1.02]). Noncardiovascular mortality at 11 years was 9.1% in the invasive group vs 8.1% in the conservative group (estimated difference, 1.0 percentage point [95% CI, -0.9 to 2.9 percentage points]; AHR, 1.18 [95% CI, 0.96-1.45]). Eleven-year restricted mean survival was not significantly different (estimated difference, 14 days [95% CI, -41 to 70 days]). CONCLUSIONS AND RELEVANCE/UNASSIGNED:In this study, long-term all-cause mortality in patients with high-risk chronic coronary disease was not significantly different after routine invasive vs initial conservative management. TRIAL REGISTRATION/UNASSIGNED:ClinicalTrials.gov Identifier: NCT04894877.
PMID: 42998244
ISSN: 1538-3598
CID: 6075522
Impact of COVID-19 Infection and Vaccination on Herpes Zoster Ophthalmicus: A Prospective Analysis From the Zoster Eye Disease Study
Niederer, Rachael L; Lee, Ting-Fang; Meyer, Jay; Hochman, Judith S; Troxel, Andrea B; Colby, Kathryn A; Warner, Daniel; Jeng, Bennie H; Cohen, Elizabeth J; ,
PURPOSE/OBJECTIVE:The aim of this study was to assess the interplay between 2 important viral infections and their management, herpes zoster ophthalmicus (HZO) and COVID-19. METHODS:A subanalysis from the Zoster Eye Disease Study, a prospective randomized controlled study examining prophylactic valacyclovir in HZO, and data collected on COVID-19 vaccination and infection from July 2020 were evaluated. Participants were included if enrolled from January 1, 2019, ensuring that their 18-month follow-up overlapped with the COVID-19 pandemic. Recurrence was defined as new or worsening stromal keratitis without ulceration, endothelial keratitis, iritis, dendritiform epithelial keratitis, or stromal keratitis with ulceration requiring a substantial increase or recommencement of topical steroid therapy. RESULTS:A total of 402 participants were included in the analysis. Attenuated zoster vaccination live was given to 35 (8.7%) and recombinant zoster vaccine to 40 (10.0%) before study commencement. No difference was observed in incidence or severity of COVID-19 infection in those with previous zoster vaccination, and no difference was observed in those treated with valacyclovir prophylaxis. COVID-19 infection occurred in 71 participants (17.7%) during the study period, and COVID-19 vaccination was received by 170 participants (42.3%). No association was observed between HZO recurrence and COVID-19 infection (P = 0.39) or vaccination (P = 0.75) during the 18-month follow-up. The study was powered to detect a hazard ratio of 1.19 for COVID-19 infection or vaccine-associated recurrence. CONCLUSIONS:No significant association was observed between zoster vaccination or valacyclovir use and COVID-19 incidence or severity. In addition, no significant increase in HZO recurrence was observed following COVID-19 infection or vaccination.
PMID: 42987223
ISSN: 1536-4798
CID: 6075491
Sex-Specific Coronary Plaque Characteristics and Risk of Cardiovascular Events: Insights from ISCHEMIA
Lakshmanan, Suvasini; Wang, Yixin; Chen, Ying Qing; Mancini, Gb John; Leipsic, Jonathan; Budoff, Matthew; Hague, Cameron; Min, James K; Stone, Gregg W; Boden, William E; Spertus, John A; Bangalore, Sripal; Hochman, Judith S; Reynolds, Harmony R; Maron, David J; ,
Among the highly diseased population of participants with chronic coronary syndromes and obstructive coronary artery disease enrolled in the ISCHEMIA trial, women had lower burden of total, calcified, non-calcified plaque and adverse plaque characteristics on CCTA compared with men. However, the risk associated with greater atherosclerotic burden was higher among females for the composite outcome of CV death or MI than males. These findings highlight important sex-specific differences in the prognostic value of coronary atherosclerotic burden and support the need to explore differential approaches to cardiovascular risk stratification in men and women.
PMID: 42966435
ISSN: 1097-6744
CID: 6074827
Accuracy of Angiographic Identification of Culprit Lesions in Women With MINOCA
Shwayder, Elianna M; Li, Vincent; Serrano Gomez, Claudia; Shah, Binita; Elbaum, Lindsay; Hochman, Judith S; Hausvater, Anaïs; Maehara, Akiko; Matsumura, Mitsuaki; Sedlak, Tara; Saw, Jacqueline; Yu, Chang; Reynolds, Harmony R; Smilowitz, Nathaniel R
BACKGROUND/UNASSIGNED:Myocardial infarction with nonobstructive coronary arteries (MINOCA) accounts for 6% to 15% of acute coronary syndromes and disproportionately affects women. Although coronary culprit lesions are present in 45% of patients with MINOCA, multivessel optical coherence tomography (OCT) is infrequently performed. We evaluated whether interventional cardiologists can identify coronary arteries with culprit lesions using invasive coronary angiography in women with MINOCA. METHODS/UNASSIGNED:Women with MINOCA who had a coronary culprit lesion identified by multivessel OCT were included. A core laboratory confirmed and localized OCT-defined culprit lesions using angiographic coregistration. Two interventional cardiologists blinded to OCT findings independently reviewed invasive coronary angiography, before and after review of ECG and transthoracic echocardiography, to identify the culprit artery. RESULTS/UNASSIGNED:=0.97). Culprit arteries were identified by at least 1 cardiologist in 87.5% of plaque rupture cases. Only 11% of circumflex lesions were identified. CONCLUSIONS/UNASSIGNED:Interventional cardiologists could not reliably identify culprit arteries using coronary angiography in women with MINOCA, even after ECG and transthoracic echocardiography review. Our findings suggest that invasive angiography alone should not guide vessel selection for intracoronary imaging and support multivessel imaging when evaluating MINOCA. REGISTRATION/UNASSIGNED:URL: https://www.clinicaltrials.gov; Unique identifier: NCT02905357.
PMID: 42717865
ISSN: 1941-7632
CID: 6072245
Health Status Relationship to Ischemia and Coronary Artery Disease Severity in the ISCHEMIA Trial
Phillips, Lawrence M; Jones, Philip G; Shaw, Leslee J; Mark, Daniel B; Berman, Daniel S; Kwong, Raymond Y; Picard, Michael H; Chaitman, Bernard R; Min, James K; Celutkiene, Jelena; Stone, Gregg W; Vitola, Joao; Moorthy, Nagaraja; Steg, Philippe Gabriel; Ong, Peter; Hueb, Whady A; Rezende, Paulo C; Hochman, Judith S; Maron, David J; Reynolds, Harmony R; Spertus, John A; ,
BACKGROUND:The ISCHEMIA trial randomized participants with chronic coronary disease and moderate or severe ischemia by site assessment to an initial invasive strategy plus guideline-directed medical therapy (GDMT) or to an initial conservative strategy of GDMT alone. This secondary analysis examines the association of pre-randomization ischemia severity, from stress testing assessed by a core laboratory, and anatomic severity of coronary artery disease (CAD), assessed by coronary computed tomography angiography (CCTA), with 1-year health status outcomes. METHODS:The associations of ischemia and CAD severity with 1-year health status were assessed using proportional odds models, adjusted for age, sex, and baseline health status and stratified by baseline angina; Seattle Angina Questionnaire (SAQ) Angina Frequency [AF] score < 100 (and angina) vs. 100 (no angina). RESULTS:Among 4,558 participants with baseline and 1-year SAQ assessments, 2936 (64.4%) had baseline angina. Among these, ischemia was categorized as no/mild (363), moderate (986) and severe (1587). Among participants reporting angina at baseline, those with severe baseline ischemia had more frequent angina compared with those having less ischemia (SAQ AF, 70.6 vs 73.0, p=0.029). However, the adjusted odds ratio for better 1-year overall health status, assessed by the SAQ Summary Score, was 1.29 (95% CI, CI 1.05-1.59, p=0.007) for participants with severe vs. those with less baseline ischemia. No differences in 1-year health status were observed by CAD severity or in asymptomatic patients categorized by ischemia or CAD severity. CONCLUSIONS:Among participants with baseline angina in the ISCHEMIA trial, severe ischemia was independently associated with more frequent angina at baseline and at 1 year, but also with better 1-year overall health status compared with less ischemia. Anatomic CAD severity was not associated with angina severity.
PMID: 42641674
ISSN: 1097-6744
CID: 6071776
Assessing the Prognostic Value of Serial Seattle Angina Questionnaire Scores in Chronic Coronary Disease
O'Keefe, Evan L; Saxon, John T; Cho, Yoon Joo; Jones, Philip G; Mark, Daniel B; Bangalore, Sripal; Boden, William E; Stone, Gregg W; Reynolds, Harmony R; Hochman, Judith S; Maron, David J; Spertus, John A; ,
BACKGROUND/UNASSIGNED:Patient-centered prognostic assessment in chronic coronary disease is vital for treatment optimization. Although the Seattle Angina Questionnaire Summary Score (SAQ-SS) correlates with clinical outcomes, clinicians lack guidance on how to weigh prior, current, or changes in scores, and whether prognostic significance varies by revascularization strategy. METHODS/UNASSIGNED:The ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches; 2012-2019) was a global, multicenter, randomized controlled trial. This secondary analysis evaluated the prognostic value of serial SAQ-SS assessments. The SAQ-SS ranges from 0 to 100, with higher scores indicating better health status. To simulate routine clinical care, the follow-up in ISCHEMIA was equated to outpatient clinic visits-we defined the 3-month SAQ-SS as the prior score and the 6-month assessment as the current score in the clinic. Analyses were stratified by treatment strategy: conservative management and invasive management with revascularization. Cox proportional hazards models assessed the association of the prior score, the current score, and the change in scores with ISCHEMIA's primary composite end point (cardiovascular death, myocardial infarction, hospitalization for unstable angina, heart failure, and resuscitated cardiac arrest), adjusting for 17 clinical covariates. RESULTS/UNASSIGNED:This analysis included 3405 participants (1965 in conservative management: 77.4% male, mean age 64.3 years±9.5; 1440 in invasive management: 77.6% male, mean age 64.0 years±9.4). Over a median follow-up of 3.2 years, 215 (11.0%) and 96 (6.7%) participants in the conservative and invasive cohorts, respectively, experienced the primary composite end point. Higher prior, current, and change SAQ-SS were each independently associated with a lower risk of cardiovascular events. In the conservative cohort, each 5-point increase in the current SAQ-SS was associated with a 7% lower risk of the primary end point (hazard ratio, 0.93 [95% CI, 0.90-0.96]); in the invasive cohort, the association was 9% (hazard ratio, 0.91 [95% CI, 0.86-0.96]). CONCLUSIONS/UNASSIGNED:In patients with chronic coronary disease, the most recent SAQ-SS is the strongest health status predictor of future cardiovascular events. Serial SAQ-SS assessments provide a practical, dynamic, and patient-centered approach for updating prognosis in chronic coronary disease management. REGISTRATION/UNASSIGNED:URL: https://www.clinicaltrials.gov; Unique identifier: NCT01471522.
PMID: 42554061
ISSN: 3068-563x
CID: 6070821
Timing, Translation, and Preparedness: Lessons Learned From COVID-19 Anticoagulation in Noncritically Ill Hospitalized Patients
Tritschler, Tobias; Fuster, Valentin; Lawler, Patrick R; Farkouh, Michael E; Marx, Caterina E; Neal, Matthew D; Sholzberg, Michelle; Spyropoulos, Alex C; Tong, Steven Y C; Muñoz-Rivas, Nuria; Blondon, Marc; Berger, Jeffrey S; Bikdeli, Behnood; Cattaneo, Marco; Cushman, Mary; Goldin, Mark; Goligher, Ewan C; Hochman, Judith S; Jüni, Peter; McQuilten, Zoe K; Morici, Nuccia; Sadeghipour, Parham; Venkatesh, Balasubramanian; Zuily, Stéphane; Amstutz, Alain; Aujesky, Drahomir; Carrier, Marc; Hofstetter, Robin V; Murthy, Srinivas; Rodger, Marc; Skeith, Leslie; Veroniki, Areti A; Hutton, Brian; Zarychanski, Ryan; Stone, Gregg W; Le Gal, Grégoire; ,
BACKGROUND:Public health emergencies require rapid generation, synthesis, and translation of clinical evidence into practice guidelines; yet, systematic synthesis of the challenges and lessons from these processes remains limited. OBJECTIVES/OBJECTIVE:The purpose of this study was to examine how evidence on anticoagulation in COVID-19 was generated and translated into clinical guidance, using randomized controlled trials (RCTs) as a case study, and to contextualize these processes with an individual participant data meta-analysis (IPDMA). METHODS:Systematic searches identified RCTs comparing therapeutic- vs nontherapeutic-dose anticoagulation in noncritically ill patients hospitalized for COVID-19. Trial characteristics, evidence accumulation, and associated guideline recommendations were summarized over time. An IPDMA was performed to estimate summary treatment effects using mixed-effects logistic regression. RESULTS:Evidence evolved from an early coordinated platform RCT (preprint May 2021) to subsequent RCTs published between June 2021 and July 2023. In exploratory counterfactual sequential IPDMA, the pooled treatment effect on organ support or death became statistically significant in May 2021, approximately 13 months after first patient enrollment (adjusted OR: 0.73; 95% CI: 0.58-0.91; 6 RCTs, n = 3,944). Guideline recommendations shifted from uniform endorsement of prophylactic-dose anticoagulation in 2020 to recommendations supporting therapeutic-dose anticoagulation in 2022, with variation in certainty across guidelines. Individual participant data were obtained after completion of data transfer in April 2024 and included 7 RCTs comprising 6,362 patients. Therapeutic-dose anticoagulation reduced the odds of organ support or death (12.9% vs 16.2%; adjusted OR: 0.81; 95% CI: 0.67-0.97). Major bleeding was rare (0.8% vs 0.5%). CONCLUSIONS:The COVID-19 anticoagulation experience highlights how delays in coordination, data sharing, and synthesis can slow the translation of evidence into practice. Therapeutic-dose anticoagulation was associated with reduced odds of organ support or death and, in this context, serves as a case study of how evidence emerges and is acted upon under conditions of uncertainty. Strengthening coordinated research networks, platform trial infrastructures, prioritized funding, and near-real-time cross-trial synthesis may improve the timeliness, reliability, and responsiveness of evidence systems during future health emergencies.
PMID: 42523015
ISSN: 1558-3597
CID: 6070438
Variability in Cardiac Stress Test Interpretation: Agreement Between Enrollment Sites and Core Laboratories in the Global ISCHEMIA Trial
O'Keefe, Evan; Sperry, Brett W; Jones, Philip G; O'Keefe, James H; Phillips, Lawrence M; Reynolds, Harmony R; Shaw, Leslee J; Berman, Daniel S; Picard, Michael H; Kwong, Raymond Y; Chaitman, Bernard R; Bateman, Timothy M; Bangalore, Sripal; Maron, David J; Hochman, Judith S; Spertus, John A; ,
BACKGROUND/UNASSIGNED:Cardiac stress testing is a cornerstone of risk stratification and management in patients with chronic coronary disease, yet the consistency and accuracy of its interpretation remain poorly defined. This analysis evaluated variation in the interpretation of myocardial ischemia between enrollment sites and core laboratories in the ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches). METHODS/UNASSIGNED:ISCHEMIA was a global (37 countries, 2012-2018) randomized trial of an initial invasive versus conservative strategy in patients with chronic coronary disease and moderate or severe ischemia. This analysis included participants with site-interpreted qualifying stress tests-nuclear, echocardiography (echo), cardiac magnetic resonance, or exercise tolerance test-and independent core laboratory adjudication. Core laboratories, serving as the reference standard, reinterpreted tests blinded to site results. A trinary outcome variable (site underestimation, concordance, or overestimation) was defined by comparing site-determined ischemia levels to standardized core lab assessments. Adjusted mixed-effects logistic regression models with random site intercepts assessed variability. RESULTS/UNASSIGNED:Among 6971 participants (mean age, 62.8 years; 73% men), site interpretations showed 0% no/mild (by design), 43% moderate, and 57% severe ischemia. Core labs reclassified these as 8% none, 11% mild, 30% moderate, and 51% severe ischemia. For the imaging modalities, median site-core lab agreement rates were ≈55%; nearly 25% of site-classified moderate/severe cases were downgraded to no or mild ischemia by core labs. Adjusted median odds ratios for site overestimation were 2.36 (95% CI, 2.02-2.82; nuclear), 1.98 (95% CI, 1.62-2.60; echo), 1.89 (95% CI, 1.0-5.41; cardiac magnetic resonance), and 2.15 (95% CI, 1.76-2.79; exercise tolerance test). Adjusted median odds ratios for underestimation ranged from 1.25 to 1.77. CONCLUSIONS/UNASSIGNED:In ISCHEMIA, enrollment sites frequently overestimated or underestimated the severity of myocardial ischemia compared with core laboratory assessments, highlighting the need for strategies to improve the consistency and accuracy of stress testing interpretation in patients with chronic coronary disease. REGISTRATION/UNASSIGNED:URL: https://www.clinicaltrials.gov; Unique identifier: NCT01471522.
PMCID:13326705
PMID: 42384892
ISSN: 3068-563x
CID: 6062992
Whole blood epigenomic and transcriptomic characterization identifies vulnerable molecular subtypes of chronic coronary disease
Muller, Matthew; Cornwell, MacIntosh G; Rajkumar, Sandhya; Chen, Ze; Coit, David; Drouard, Gabin; Sastourne-Haletou, Paul; Yang, Huan; Raitakari, Olli; Lehtimäki, Terho; Hochman, Judith; Maron, David J; Berger, Jeffrey S; Newman, Jonathan D; Ruggles, Kelly V; ,
Chronic coronary disease (CCD) remains a leading cause of morbidity and mortality worldwide. However, current clinical assessments, including tests of inducible ischemia or coronary artery disease severity poorly discriminate risk for future cardiovascular (CV) disease events among this population with established CCD. To address this gap, our study leverages high-dimensional molecular data from the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) Trials biorepository to molecularly characterize patients with CCD. By integrating transcriptomic (N = 646) and methylomic (N = 732) data with core-lab confirmed clinical phenotyping, we describe molecular signatures associated with disease severity and identify distinct whole-blood molecular subtypes of CCD. These subtypes demonstrate differential risks of CV events, independent of traditional clinical risk scores, and have distinct molecular and immune profiles. Validation of the transcriptomic and methylomic subtypes in two independent external cohorts confirms the clinical relevance and generalizability of our findings. These findings underscore the potential of blood-based multi-omic approaches to refine risk stratification, improve personalized treatment strategies and advance secondary prevention in CCD. Clinical Trial Registration: ClinicalTrials.gov identifier: NCT01471522; https://clinicaltrials.gov/ct2/show/NCT01471522.
PMID: 42303606
ISSN: 2041-1723
CID: 6049722